{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:29:45Z","timestamp":1792654185482,"version":"4.5.0"},"reference-count":57,"publisher":"IMR Press","issue":"1","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Coronary angioplasty was first introduced in 1977. From plain old balloon angioplasty to the introduction of bare metal stents in 1986 and dual antiplatelet therapy in 1992 to much more later on. Due to the unacceptable rate of stent restenosis, drug eluting stents (DES) were introduced in 2000. The first generation showed an increase in late stent thrombosis which led to the introduction of the second generation DES with biocompatible or biodegradable polymers and thinner platforms. However very late stent thrombosis and late restenosis might still pose problems in the latter. Furthermore, there has been major debate regarding the impact of long-term vessel caging on normal vasomotricity and long-term positive remodeling. To resolve these issues, the bioresorbable vascular scaffolds (BVS) were launched into the real world in 2011, showing promising initial results. Multiple randomized trials, meta-analyses, and registries were performed, mainly with the Absorb Bioresorbable Vascular Scaffold System (Abbott Vascular, Chicago, IL, USA). This new technology is hindered by certain features, such as the BVS radial strength, its strut thickness, and the inflammatory process related to scaffold degradation. Moreover, there is known data indicating higher thrombosis rate with the Absorb BVS compared with the new generation of DES, despite similar cardiovascular death. In this review, we discuss the clinical procedural and technical evidence on BVS, with emphasis on their clinical impact. We finally tackle the future directions on device and procedural improvement while asking: is the bioresorbable technology still the way to the future?<\/jats:p>","DOI":"10.31083\/j.rcm.2021.01.225","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:44:00Z","timestamp":1617324240000},"source":"Crossref","is-referenced-by-count":14,"title":["Update on coronary artery bioresorbable vascular scaffolds in percutaneous coronary revascularization"],"prefix":"10.31083","volume":"22","author":[{"given":"Nagi","family":"Azzi","sequence":"first","affiliation":[{"name":"Department of Cardiology, Lebanese American University - Rizk Hospital, 1100 Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Shatila","sequence":"first","affiliation":[{"name":"Department of Cardiology, Texas Heart Institute, Houston, TX 77030, USA"},{"name":"Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelb\u00e6k H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. New England Journal of Medicine. 2007; 356: 1030-1039.","DOI":"10.1056\/NEJMoa067484"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Holmes DR, Kereiakes DJ, Laskey WK, Colombo A, Ellis SG, Henry TD, et al. Thrombosis and drug-eluting stents: an objective appraisal. Journal of the American College of Cardiology. 2007; 50: 109-118.","DOI":"10.1016\/j.jacc.2007.04.032"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Reyes R, Moreno R, S\u00e1nchez-Recalde A, Navarro F, Franco J, Pi\u00f1ero A, et al. Comparison of the safety between first- and second-generation drug eluting stents. International Journal of Cardiology. 2012; 160: 181-186.","DOI":"10.1016\/j.ijcard.2011.04.004"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Nishio S, Kosuga K, Igaki K, Okada M, Kyo E, Tsuji T,et al. Long-term (> 10 years) clinical outcomes of first in humans biodegradable poly-l-lactic acid coronary stents Igaki-Tamai stents. Circulation. 2012; 125 : 2343-2352.","DOI":"10.1161\/CIRCULATIONAHA.110.000901"},{"key":"ref5","unstructured":"Tarantini G, Saia F, Capranzano P, Cortese B, Mojoli M, Boccuzzi G, et al. SICI-GISE Position paper: use of Absorb BVS in clinical practice. Giornale Italiano di Cardiologia. 2016; 17: 28S-44S. (In Italian)"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Indolfi C, De Rosa S, Colombo A. Bioresorbable vascular scaffolds - basic concepts and clinical outcome. Nature Reviews Cardiology. 2016; 13: 719-729.","DOI":"10.1038\/nrcardio.2016.151"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns R, de Bruyne B, et al. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention. 2014; 9: 1271-1284.","DOI":"10.4244\/EIJV9I11A217"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carri\u00e9 D, Piek JJ, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomized, controlled, single-blind, multicentre clinical trial. The Lancet. 2016; 388: 2479-2491.","DOI":"10.1016\/S0140-6736(16)32050-5"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Onuma Y, Sotomi Y, Shiomi H, Ozaki Y, Namiki A, Yasuda S, et al. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. EuroIntervention. 2016; 12: 1090-1101.","DOI":"10.4244\/EIJY16M09_01"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Okada K, Honda Y, Kitahara H, Ikutomi M, Kameda R, Brooke Hollak M, et al. Scaffold underexpansion and late lumen loss after bioresorbable scaffold implantation: insights from ABSORB JAPAN trial. IJC Heart & Vasculature. 2020; 31: 100623.","DOI":"10.1016\/j.ijcha.2020.100623"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Arroyo D, Gendre G, Schukraft S, Kallinikou Z, M\u00fcller O, Baeriswyl G, et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: two-year clinical outcomes of the EVERBIO II trial. International Journal of Cardiology. 2017; 243: 121-125.","DOI":"10.1016\/j.ijcard.2017.05.053"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Sabat\u00e9 M, Windecker S, I\u00f1iguez A, Okkels-Jensen L, Cequier A, Brugaletta S, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST segment elevation myocardial infarction: results of the randomized ABSORB ST segment elevation myocardial infarction-TROFI II trial. European Heart Journal. 2016; 37: 229-240.","DOI":"10.1093\/eurheartj\/ehv500"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Gomez-Lara J, Brugaletta S, Ortega-Paz L, Vandeloo B, Moscarella E, Salas M, et al. Long-term coronary functional assessment of the infarct-related artery treated with everolimus-eluting bioresorbable scaffolds or everolimus-eluting metallic stents: insights of the TROFI II trial. JACC. Cardiovascular Interventions. 2018; 11: 1559-1571.","DOI":"10.1016\/j.jcin.2018.04.026"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS, et al. 3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds. Journal of the American College of Cardiology. 2017; 70: 2852-2862.","DOI":"10.1016\/j.jacc.2017.10.010"},{"key":"ref15","unstructured":"Lou N, Writer S. FDA Probing Absorb Stent - higher risk of stent thrombosis and MI under Investigation. MedPage Today. 2017."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Kereiakes DJ, Ellis SG, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. Clinical outcomes before and after complete everolimus-eluting bioresorbable scaffold resorption. Circulation. 2019; 140: 1895-1903.","DOI":"10.1161\/CIRCULATIONAHA.119.042584"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Wykrzykowska JJ, Kraak RP, Hofma SH, van der Schaaf RJ, Arkenbout EK, IJsselmuiden AJ, et al. Bioresorbable scaffolds vs. metallic stents in routine PCI. The New England Journal of Medicine. 2017; 376: 2319-2328.","DOI":"10.1056\/NEJMoa1614954"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Abizaid A, Ribamar Costa J, Bartorelli AL, Whitbourn R, van Geuns RJ, Chevalier B, et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention. 2015; 10: 1396-1401.","DOI":"10.4244\/EIJV10I12A243"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Rzeszutko \u0141, Siudak Z, W\u0142odarczak A, Lekston A, Depukat R, Ocha\u0142a A, et al. Contemporary use of bioresorbable vascular scaffolds (BVS) in patients with stable angina and acute coronary syndromes. Polish National Registry. Kardiologia Polska. 2014; 72: 1394-1399.","DOI":"10.5603\/KP.a2014.0147"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Ielasi A, Cortese B, Moscarella E, Loi B, Tarantini G, Varricchio A, et al. One-year clinical outcomes after unrestricted implantation of the Absorb bioresorbable scaffold (RAI registry). EuroIntervention. 2018; 14: e546-e553.","DOI":"10.4244\/EIJ-D-17-00443"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015; 10: 1144-1153.","DOI":"10.4244\/EIJY14M07_11"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Hellenkamp K, Becker A, Gabriel YD, Hasenfu\u00df G, H\u00fcnlich M, Jacobshagen C, et al. Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: data of the BVS registry G\u00f6ttingen predominantly from ACS patients. International Journal of Cardiology. 2017; 234: 58-63.","DOI":"10.1016\/j.ijcard.2017.02.069"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Wiebe J, Hoppmann P, Colleran R, Kufner S, Valeskini M, Cassese S, et al. Long-term clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine practice: 2-year results of the ISAR-ABSORB Registry. JACC: Cardiovascular Interventions. 2017; 10: 1222-1229.","DOI":"10.1016\/j.jcin.2017.03.029"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Lipinski MJ, Escarcega RO, Baker NC, Benn HA, Gaglia MA, Torguson R, et al. Scaffold thrombosis after percutaneous coronary intervention with absorb bioresorbable vascular scaffold: a systematic review and meta-analysis. JACC: Cardiovascular Interventions. 2016; 9: 12-24.","DOI":"10.1016\/j.jcin.2015.09.024"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Collet C, Asano T, Sotomi Y, Cavalcante R, Miyazaki Y, Zeng Y, et al. Early, late and very late incidence of bioresorbable scaffold thrombosis: a systematic review and meta-analysis of randomized clinical trials and observational studies. Minerva Cardioangiologica. 2017; 65: 32-51.","DOI":"10.23736\/S0026-4725.16.04238-9"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Collet C, Asano T, Miyazaki Y, Tenekecioglu E, Katagiri Y, Sotomi Y, et al. Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal. 2017; 38: 2559-2566.","DOI":"10.1093\/eurheartj\/ehx155"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Polimeni A, Anadol R, M\u00fcnzel T, Indolfi C, De Rosa S, Gori T. Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs. BMC Cardiovascular Disorders. 2017; 17: 147.","DOI":"10.1186\/s12872-017-0586-2"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Elias J, van Dongen IM, Kraak RP, Tijssen RYG, Claessen BEPM, Tijssen JGP, et al. Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds vs. metallic everolimus-eluting stents in coronary artery disease: a weighted meta-analysis of seven randomised controlled trials including 5577 patients. Netherlands Heart Journal. 2017; 25: 429-438.","DOI":"10.1007\/s12471-017-1008-x"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Sorrentino S, Giustino G, Mehran R, Kini AS, Sharma SK, Faggioni M, et al. Everolimus-eluting bioresorbable scaffolds vs. everolimus-eluting metallic stents. Journal of the American College of Cardiology. 2017; 69: 3055-3066.","DOI":"10.1016\/j.jacc.2017.04.011"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Elias J, van Dongen IM, Kraak RP, Tijssen RYG, Claessen BEPM, Tijssen JGP, et al. Mid-term clinical outcomes with everolimus-eluting bioresorbable scaffolds vs. everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomized trials. EuroIntervention. 2017; 25: 429-438.","DOI":"10.1007\/s12471-017-1008-x"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"De Rosa R, Silverio A, Varricchio A, De Luca G, Di Maio M, Radano I, et al. Meta-analysis comparing outcomes after everolimus-eluting bioresorbable vascular scaffolds vs. everolimus-eluting metallic stents in patients with acute coronary syndromes. The American Journal of Cardiology. 2018; 122: 61-68.","DOI":"10.1016\/j.amjcard.2018.03.003"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Ni L, Chen H, Luo Z, Yu Y. Bioresorbable vascular stents and drug-eluting stents in treatment of coronary heart disease: a meta-analysis. Journal of Cardiothoracic Surgery. 2020; 15: 26.","DOI":"10.1186\/s13019-020-1041-5"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Ke J, Zhang H, Huang J, Lv P, Chen Y, Xu K, et al. Three-year outcomes of bioresorbable vascular scaffolds vs. second-generation drug-eluting stents. Medicine. 2020; 99: e21554.","DOI":"10.1097\/MD.0000000000021554"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Ke J, Zhang H, Huang J, Lv P, Yan J. Mid-term outcomes of bioresorbable vascular scaffolds vs second-generation drug-eluting stents in patients with acute coronary syndromes. Medicine. 2020; 99: e19458.","DOI":"10.1097\/MD.0000000000019458"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Alfonso F, Cuesta J, P\u00e9rez-Vizcayno MJ, Garc\u00eda Del Blanco B, Rumoroso JR, Bosa F, et al. Bioresorbable vascular scaffolds for patients with in-stent restenosis: the RIBS VI study. JACC: Cardiovascular Interventions. 2017; 10: 1841-1851.","DOI":"10.1016\/j.jcin.2017.06.064"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Abizaid A, Costa RA, Schofer J, Ormiston J, Maeng M, Witzenbichler B, et al. Serial multimodality imaging and 2-year clinical outcomes of the novel desolve novolimus-eluting bioresorbable coronary scaffold system for the treatment of single de novo coronary lesions. JACC: Cardiovascular Interventions. 2016; 9: 565-574.","DOI":"10.1016\/j.jcin.2015.12.004"},{"key":"ref37","unstructured":"Lafont A. ARTDIVA. Presented at BRS. 2014."},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Haude M, Ince H, Kische S, Abizaid A, T\u00f6lg R, Alves Lemos P, et al. Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III. EuroIntervention. 2017; 13: 432-439.","DOI":"10.4244\/EIJ-D-17-00254"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Ozaki Y, Garcia-Garcia HM, Shlofmitz E, Hideo-Kajita A, Waksman R. Second-generation drug-eluting resorbable magnesium scaffold: review of the clinical evidence. Cardiovascular Revascularization Medicine. 2020; 21: 127-136.","DOI":"10.1016\/j.carrev.2019.10.012"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B, et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? European Heart Journal. 2012; 33: 1325-1333.","DOI":"10.1093\/eurheartj\/ehr466"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Ishida K, Giacchi G, Brugaletta S, Garc\u00eda-\u00c1lvarez A, Sabat\u00e9 M. Unfavorable bioresorbable vascular scaffold resorption, a cause of restenosis? Cardiovascular Revascularization Medicine. 2016; 17: 571-573.","DOI":"10.1016\/j.carrev.2016.05.013"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Kawamoto H, Jabbour RJ, Tanaka A, Latib A, Colombo A. The bioresorbable scaffold: will oversizing affect outcomes? JACC: Cardiovascular Interventions. 2016; 9: 299-300.","DOI":"10.1016\/j.jcin.2015.11.019"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Puricel S, Cuculi F, Weissner M, Schmermund A, Jamshidi P, Nyffenegger T, et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. Journal of the American College of Cardiology. 2016; 67: 921-931.","DOI":"10.1016\/j.jacc.2015.12.019"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Sorrentino S, De Rosa S, Ambrosio G, Mongiardo A, Spaccarotella C, Polimeni A, et al. The duration of balloon inflation affects the luminal diameter of coronary segments after bioresorbable vascular scaffolds deployment. BMC Cardiovascular Disorders. 2015; 15: 169.","DOI":"10.1186\/s12872-015-0163-5"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Suwannasom P, Sotomi Y, Ishibashi Y, Cavalcante R, Albuquerque FN, Macaya C, et al. The impact of post-procedural asymmetry, expansion, and eccentricity of bioresorbable everolimus-eluting scaffold and metallic everolimus-eluting stent on clinical outcomes in the ABSORB II trial. JACC. Cardiovascular Interventions. 2016; 9: 1231-1242.","DOI":"10.1016\/j.jcin.2016.03.027"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Tanaka A, Latib A, Kawamoto H, Jabbour RJ, Sato K, Miyazaki T, et al. Clinical outcomes of a real world cohort following bioresorbable vascular scaffold implantation utilizing an optimized implantation strategy. EuroIntervention. 2017; 12: 1730-1737.","DOI":"10.4244\/EIJ-D-16-00247"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Capodanno D, Angiolillo DJ. Antiplatelet therapy after implantation of bioresorbable vascular scaffolds. JACC: Cardiovascular Interventions. 2017; 10: 425-437.","DOI":"10.1016\/j.jcin.2016.12.279"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Stone GW, Granada JF. Very Late Thrombosis after bioresorbable scaffolds: cause for concern? Journal of the American College of Cardiology. 2015; 66: 1915-1917.","DOI":"10.1016\/j.jacc.2015.08.863"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Sotomi Y, Suwannasom P, Serruys PW, Onuma Y. Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. EuroIntervention. 2017; 12: 1747-1756.","DOI":"10.4244\/EIJ-D-16-00471"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Chan CY, Wu EB, Yan BP. Very late bioresorbable scaffold thrombosis caused by intraluminal scaffold dismantling. JACC: Cardiovascular Interventions. 2016; 9: 1844-1847.","DOI":"10.1016\/j.jcin.2016.05.041"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Bourantas CV, Papafaklis MI, Kotsia A, Farooq V, Muramatsu T, Gomez-Lara J, et al. Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation: an optical coherence tomography study. JACC: Cardiovascular Interventions. 2014; 7: 315-324.","DOI":"10.1016\/j.jcin.2013.05.034"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Waksman R. Bioresorbable scaffolds polymer troubleshooting or simply not good enough?. JACC: Cardiovascular Interventions. 2017; 10: 1131-1133.","DOI":"10.1016\/j.jcin.2017.04.006"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Indolfi C, Mongiardo A, Spaccarotella C, Caiazzo G, Torella D, De Rosa S. Neointimal proliferation is associated with clinical restenosis 2 years after fully bioresorbable vascular scaffold implantation. Circulation Cardiovascular Imaging. 2014; 7: 755-757.","DOI":"10.1161\/CIRCIMAGING.114.001727"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Sotomi Y, Onuma Y, Collet C, Tenekecioglu E, Virmani R, Kleiman NS, et al. Bioresorbable scaffold: the emerging reality and future directions. Circulation Research. 2017; 120: 1341-1352.","DOI":"10.1161\/CIRCRESAHA.117.310275"},{"key":"ref55","unstructured":"Stone GW. A bioresorbable everolimus-eluting scaffold vs. a metallic everolimus-eluting stent IV - ABSORB IV. 2018. Available at: http:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2017\/10\/30\/16\/03\/absorb-iv (Accessed: 24 October 2020)."},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Kawashima H, Zocca P, Buiten RA, Smits PC, Onuma Y, Wykrzykowska JJ, et al. The 2010s in clinical drug-eluting stent and bioresorbable scaffold research: a Dutch perspective. Netherlands Heart Journal. 2020; 28: 78-87.","DOI":"10.1007\/s12471-020-01442-w"},{"key":"ref57","unstructured":"O\u2019Riordan M. New bioresorbable scaffold, magmaris, delivers positive early outcomes. 2018. Available at: https:\/\/www.tctmd.com\/news\/new-bioresorbable-scaffold-magmaris-delivers-positive-early-outcomes (Accessed: 24 October 2020)."}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/1\/10.31083\/j.rcm.2021.01.225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T17:06:18Z","timestamp":1732727178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/1\/10.31083\/j.rcm.2021.01.225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"alternative-id":["1617068614798-1520393906"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm.2021.01.225","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"article-number":"137"}}